Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell depleting therapy with rituximab

  • Stasi R
  • Cooper N
  • Poeta G
 et al. 
  • 16

    Readers

    Mendeley users who have this article in their library.
  • 211

    Citations

    Citations of this article.

Abstract

The effects of B-cell depletion with ritux-imab on regulatory T cells (Tregs) have not been determined. We investigated Tregs in patients receiving rituximab for chronic idiopathic thrombocytopenic purpura (ITP). The peripheral blood Tregs, identified as CD4+FOXP3+ T cells, were measured by flow cytometry prior to and after the immunotherapy. In addition, Tregs were analyzed for their usage of the T-cell receptor (TCR) p-variable (VB) region gene as well as their regulatory function as assessed by cell proliferation assays. Pretreatment data revealed a reduced number and a defective suppressive capacity of Tregs in ITP patients compared with control individuals. In addition, Tregs showed a polyclonal spectra-type. Patients, particularly responders, showed restored numbers of Tregs as well as a restored regulatory function upon treatment with rituximab. These results indicate that patients with active ITP have a defective T regulatory cell compartment that can be modulated by a B cell-targeted therapy. (copyright) 2008 by The American Society of Hematology.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Roberto Stasi

  • Nichola Cooper

  • Giovanni Del Poeta

  • Elisa Stipa

  • Maria Laura Evangelista

  • Elisabetta Abruzzese

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free